Workflow
VisheeNEO物理因子工作站
icon
Search documents
【伟思医疗(688580.SH)】25Q3营收稳步增长,基石新兴业务双轮驱动——2025三季度报告点评(王明瑞/黎一江/黄素青)
光大证券研究· 2025-10-26 23:04
点击注册小程序 查看完整报告 特别申明: 本订阅号中所涉及的证券研究信息由光大证券研究所编写,仅面向光大证券专业投资者客户,用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户,请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限,若给您造成不便,敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件: 公司发布2025年三季度报告。2025年前三季度,公司实现营业收入3.26亿元,同比增长11.58%;归母净利 润1.02亿元,同比增长30.68%;扣非归母净利润0.94亿元,同比增长37.35%。其中,2025年Q3实现营收 1.15亿元,同比增长14.87%;归母净利润0.33亿元,同比增长14.99%;扣非归母净利润0.30亿元,同比增 长21.61%。 点评: 25Q3营收稳步增长,经营现金流净额增加 25Q3公司归母净利润同比增长14.99%,扣非归母净利润同比增长21.61%,主要系公司销售收入增加,期 间费用率下降所致。25Q3公司的经营活动产生的现金流量净额同比增长33.74%,主要系销售商品收到的 ...
伟思医疗(688580):25Q3营收稳步增长,基石新兴业务双轮驱动:——伟思医疗(688580.SH)2025年三季度报告点评
EBSCN· 2025-10-26 12:23
Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Insights - The company achieved steady revenue growth in Q3 2025, with total revenue reaching 326 million yuan, a year-on-year increase of 11.58%. The net profit attributable to shareholders was 102 million yuan, up 30.68% year-on-year [1][2]. - The company is focusing on innovation and expanding its emerging business sectors, particularly in mental health, pelvic floor, and neurological rehabilitation, while also enhancing its aesthetic medicine and urology segments [2][3]. - The company has established a comprehensive closed-loop system for neurological rehabilitation, covering diagnosis, treatment, and rehabilitation, with several products in various stages of development [3]. Financial Performance Summary - For Q3 2025, the company reported revenue of 115 million yuan, a 14.87% increase year-on-year, and a net profit of 33 million yuan, reflecting a 14.99% growth [1][2]. - The operating cash flow increased by 33.74% year-on-year, primarily due to higher cash receipts from sales [2]. - The company’s R&D expenses were 11 million yuan, accounting for 9.76% of revenue, highlighting its commitment to innovation [2]. Profit Forecast and Valuation - The projected net profit for 2025 is 131 million yuan, with a corresponding P/E ratio of 36 times [4][3]. - The company is positioned as a leader in the magnetic-electric rehabilitation device sector, benefiting from the growing rehabilitation industry and consumer spending upgrades [3].